UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 3.528

Sortiert nach

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models

Molecular cancer therapeutics, 2020-05, Vol.19 (5), p.1091-1101

2020

Volltextzugriff (PDF)

In vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Science (American Association for the Advancement of Science), 2004-02, Vol.303 (5659), p.844-848

2004

Volltextzugriff (PDF)

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Journal of medicinal chemistry, 2013-07, Vol.56 (14), p.5979-5983

2013

Volltextzugriff (PDF)

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Proceedings of the National Academy of Sciences - PNAS, 2013-09, Vol.110 (36), p.E3445-E3454

2013

Volltextzugriff (PDF)

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8), p.2587-2597

2013

Volltextzugriff (PDF)

Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814

Molecular cancer research, 2019-12, Vol.17 (12), p.2457-2468

2019

Volltextzugriff (PDF)

p53 Activation by Small Molecules: Application in Oncology

Journal of medicinal chemistry, 2005-07, Vol.48 (14), p.4491-4499

Vassilev, Lyubomir T

2005

Volltextzugriff (PDF)

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2 -amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

The lancet oncology, 2012-11, Vol.13 (11), p.1133-1140

2012

Volltextzugriff (PDF)

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Proceedings of the National Academy of Sciences - PNAS, 2012-07, Vol.109 (29), p.11788-11793

2012

Volltextzugriff (PDF)

Cell Cycle Synchronization at the G2/M Phase Border by Reversible Inhibition of CDK1

Cell cycle (Georgetown, Tex.), 2006-11, Vol.5 (22), p.2555-2556

Vassilev, Lyubomir T

2006

Volltextzugriff (PDF)

Small-Molecule MDM2 Antagonists Reveal Aberrant P53 Signaling in Cancer: Implications for Therapy

Proceedings of the National Academy of Sciences - PNAS, 2006-02, Vol.103 (6), p.1888-1893

2006

Volltextzugriff (PDF)

Selective Small-Molecule Inhibitor Reveals Critical Mitotic Functions of Human CDK1

Proceedings of the National Academy of Sciences - PNAS, 2006-07, Vol.103 (28), p.10660-10665

2006

Volltextzugriff (PDF)

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies

Molecular cancer therapeutics, 2022-06, Vol.21 (6), p.859-870

2022

Volltextzugriff (PDF)

Targeting the p53-MDM2 interaction to treat cancer

British journal of cancer, 2004-10, Vol.91 (8), p.1415-1419

2004

Volltextzugriff (PDF)

Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics

Cell cycle (Georgetown, Tex.), 2004-04, Vol.3 (4), p.419

Vassilev, Lyubomir T

2004

Volltextzugriff (PDF)

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

Scientific reports, 2021-06, Vol.11 (1), p.12148-14, Article 12148

2021

Volltextzugriff (PDF)

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

Blood, 2005-11, Vol.106 (9), p.3150-3159

2005

Volltextzugriff (PDF)

p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation

Oncogene, 2011-01, Vol.30 (3), p.346-355

2011

Volltextzugriff (PDF)

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5

Blood, 2008-04, Vol.111 (7), p.3742-3750

2008

Volltextzugriff (PDF)

MDM2 inhibitors for cancer therapy

Trends in molecular medicine, 2007-01, Vol.13 (1), p.23-31

Vassilev, Lyubomir T

2007

Volltextzugriff (PDF)

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells

Cell reports (Cambridge), 2016-03, Vol.14 (8), p.1858-1866

2016

Volltextzugriff (PDF)

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

Cancer research (Chicago, Ill.), 2005-03, Vol.65 (5), p.1918-1924

2005

Volltextzugriff (PDF)

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia

Frontiers in oncology, 2020-02, Vol.10, p.127

2020

Volltextzugriff (PDF)

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

Oncogene, 2007-05, Vol.26 (24), p.3473-3481

2007

Volltextzugriff (PDF)

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

Blood, 2005-11, Vol.106 (10), p.3609-3617

2005

Volltextzugriff (PDF)

1 – 25 von 3.528

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.496)
Mit Volltextzugriff
(3.198)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.781)
Life Sciences & Biomedicine
(871)
Technology
(603)
Physical Sciences
(540)
Humans
(497)
Physics
(284)
Exact Sciences And Technology
(282)
Animals
(270)
Chemistry
(252)
Engineering
(224)
Biological And Medical Sciences
(222)
Materials Science
(211)
Female
(201)
Male
(184)
Materials Science, Multidisciplinary
(178)
Computer Science
(147)
Biochemistry & Molecular Biology
(133)
Fundamental And Applied Biological Sciences. Psychology
(133)
Mice
(117)
Applied Sciences
(111)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models

In vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814

p53 Activation by Small Molecules: Application in Oncology

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2 -amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Cell Cycle Synchronization at the G2/M Phase Border by Reversible Inhibition of CDK1

Small-Molecule MDM2 Antagonists Reveal Aberrant P53 Signaling in Cancer: Implications for Therapy

Selective Small-Molecule Inhibitor Reveals Critical Mitotic Functions of Human CDK1

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies

Targeting the p53-MDM2 interaction to treat cancer

Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5

MDM2 inhibitors for cancer therapy

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

Suchergebnisse filtern